Our vision for this initiative was that molecular (proteomic and genomic) signatures of cancer may be used to direct optimal and effective therapy selection, thereby enabling personalized treatment for individual patients. After the completion of a pilot study in non-small-cell lung cancer, PPM-3 aims at implementing molecular diagnostics platforms with innovative biomarkers to make a direct impact on clinical practices in Luxembourg.
The programme is divided into three categories: discovery, translation, and validation performed by multi-disciplinary team and international collaborations. Specific subjects in each category are shown in the diagram. The PPM-3 now includes malignant brain tumour in the discovery phase, and will expand to other types of cancer.
Head of research project
Dr. Yeoun Jin Kim is leading a biomarker program: the Partnership for Personalized Medicine (PPM) in the Department of Oncology.
Previously, she has been working in the pharmaceutical and biotech industries in the US, in companies such as Bristol-Myers Squibb (Princeton, NJ) (2008-2010) and Celera (Rockville, MD) (2003-2007) where she applied proteomics-based technologies to drug development. Her current interest is the translational research focusing on the biomarker discovery and development in oncology which leads to the companion diagnostics.